Benefit of immune checkpoint inhibitors as adjuvant treatment for acral melanomas
Journal of the European Academy of Dermatology and Venereology · 2026
DOI: 10.1111/jdv.70136 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2026. Verfasst von Damien Sanogo und 13 weiteren Autor:innen. Beteiligte Einrichtung: UNICAEN, INSERM U1086 ANTICIPE, Biology Research Building, Normandy University, Caen, France. Hauptthemen laut MEDLINE: Melanoma, Immune Checkpoint Inhibitors, Skin Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Solar factors play no role in the development of acral melanoma (AM). AM is characterized by low cumulative solar damage (low CSD). Responses to immunotherapy are correlated with mutational load, which, in turn, is correlated with high cumulative sun damage (CSD). This suggests that AM patients may have poor responses to immunotherapy. The clinical benefit and safety profile of adjuvant immunotherapies in AM treatment have not been fully investigated.
Objectives
To investigate whether the use of adjuvant immunotherapy for treating patients with AM in Stages IIb, IIc, III and IV NED (no evidence of disease) improves distant metastasis‐free survival.
Methods
Among the 1005 AM patients in the RIC‐Mel melanoma database, 64 AM patients who were treated with adjuvant immunotherapy were included in this study. We then calculated a propensity score to make the adjuvant immunotherapy‐treated ( n = 64) group and the untreated group ( n = 64) comparable in all respects.
Results
The use of adjuvant immunotherapy for treating AM offers no clear benefit in terms of relapse‐free survival or distant metastasis‐free survival (RFS: HR = 0.84 [0.534, 1.324, 95% CI] and DMFS: HR = 0.94 [0.565, 1.562, 95% CI]). Among the AM patients who received adjuvant immune checkpoint inhibitors (ICI), 18.8% experienced severe (Grades 3–4) immune‐related adverse events.
Conclusions
The benefit–risk balance must be carefully weighed, including the relapse‐free survival (RFS), distant metastasis‐free survival (DMFS) and rate of severe immune‐related adverse events (irAE) occurrence. Other therapeutic strategies should be investigated in larger studies to confirm the potential limited clinical benefit of this treatment strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UNICAEN, INSERM U1086 ANTICIPE, Biology Research Building, Normandy University, Caen, France.
- Dermatology Unit, Caen-Normandie University Hospital, Caen, France.
- Clinical Oncology Department, Caen, Centre, France.
- Dermatology Unit, Nantes University Hospital, Nantes, France.
- Nantes University, Nantes, France.
- Dermatology Unit, Valence Hospital, Valence, France.
ORCID-Profile: Romain Levard, Henri Montaudié, Florence Brunet-Possenti, Brigitte Dreno, Jean-Matthieu L'Orphelin
Zitieren
APA
Sanogo, D., Levard, R., Cassecuel, J., Khammari, A., Quereux, G., Grange, F., Montaudié, H., Brunet-Possenti, F., Lavaud, J., Leccia, M. T., Jeudy, G., Dompmartin, A., Dreno, B., & L'Orphelin, J. M. (2026). Benefit of immune checkpoint inhibitors as adjuvant treatment for acral melanomas. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.70136
Vancouver
Sanogo D, Levard R, Cassecuel J, Khammari A, Quereux G, Grange F, et al. Benefit of immune checkpoint inhibitors as adjuvant treatment for acral melanomas. Journal of the European Academy of Dermatology and Venereology. 2026. doi:10.1111/jdv.70136
BibTeX
@article{Sanogo2026,
author = {Sanogo, Damien and Levard, Romain and Cassecuel, Julie and Khammari, Amir and Quereux, Gaelle and Grange, Florent and Montaudié, Henri and Brunet-Possenti, Florence and Lavaud, Justine and Leccia, Marie-Thérèse and Jeudy, Géraldine and Dompmartin, Anne and Dreno, Brigitte and L'Orphelin, Jean-Matthieu},
title = {Benefit of immune checkpoint inhibitors as adjuvant treatment for acral melanomas},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2026},
doi = {10.1111/jdv.70136}
}
EUVIMED